• Is Sentinel Lymph Node Biopsy Necessary in Patients who Undergo Prophylactic Mastectomy?
    • Madan V, Mamounas EP.
    • Clin Breast Cancer. 2022 Dec 7:S1526-8209(22)00271-3. doi: 10.1016/j.clbc.2022.12.003. Epub ahead of print.
    • Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated?
    • Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, Meterissian S, Aleynikova O, Wong N, Foulkes WD.
    • Ann Surg Oncol. 2022 Oct;29(11):6660-6668. doi: 10.1245/s10434-022-11916-3. Epub 2022 May 26.
    • ASO Author Reflections: Sentinel Lymph Node Biopsy in BRCA1/2 Germline Pathogenic Variant Carriers Undergoing Risk-Reducing Mastectomy.
    • Ferroum A, Wong SM.
    • Ann Surg Oncol. 2022 Oct;29(11):6669-6670. doi: 10.1245/s10434-022-12013-1. Epub 2022 Jun 16.
    • Commentary
    • ASO Visual Abstract: Incidence of Occult Breast Cancer in Carriers of BRCA1/2 and Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy-When is Sentinel Lymph Node Biopsy Indicated?
    • Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, Meterissian S, Aleynikova O, Wong N, Foulkes WD.
    • Ann Surg Oncol. 2022 Oct;29(11):6671-6672. doi: 10.1245/s10434-022-12011-3.
    • Prophylactic mastectomy and occult malignancy: Surgical and imaging considerations.
    • Thompson JL, Sinco BR, McCaffrey RL, Chang AE, Sabel MS, Dossett LA, Hughes TM, Jeruss JS.
    • J Surg Oncol. 2022 Sep 7. doi: 10.1002/jso.27088. Epub ahead of print.
    • Surgical Outcome Measures in a Cohort of Patients at High Risk of Breast Cancer Treated by Bilateral Risk Reducing Mastectomy and Breast Reconstruction.
    • Gandhi A, Duxbury P, Clancy T, Lalloo F, Wisely JA, Kirwan CC, Foden P, Stocking K, Howell A, Evans DG.
    • Plast Reconstr Surg. 2022 Sep 1;150(3):496e-505e. doi: 10.1097/PRS.0000000000009383. Epub 2022 Jun 24.
    • Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
    • John CS, Fong A, Alban R, Gillen J, Moore KM, Walsh CS, Li AJ, Rimel BJ, Amersi F, Cass I.
    • Gynecol Oncol. 2022 Jan;164(1):202-207. doi: 10.1016/j.ygyno.2021.10.077. Epub 2021 Nov 30.
    • Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center.
    • Mittal A, Deo SVS, Gogia A, Batra A, Kumar A, Bhoriwal S, Deb KS, Dhamija E, Thulkar S, Ramprasad VL, Olopade O, Pramanik R.
    • Ann Surg Oncol. 2021 Oct 2:1–10. doi: 10.1245/s10434-021-10870-w. Epub ahead of print.
    • Chirurgie de réduction de risque mammaire et découverte fortuite de cancer : dix ans d’expérience dans un centre de lutte contre le cancer [Prophylactic mastectomy and occult cancer: a ten-year experience at a cancer center].
    • Mangiardi-Veltin M, Chamming's F, Jaffre A, Rousvoal A, Tunon de Lara C, Brouste V, Hoppe S, Sénéchal C.
    • Bull Cancer. 2021 Sep 20:S0007-4551(21)00298-8. French. doi: 10.1016/j.bulcan.2021.05.007. Epub ahead of print.
    • [Article in French]
    • Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women.
    • Evans DG, Howell SJ, Gandhi A, van Veen EM, Woodward ER, Harvey J, Barr L, Wallace A, Lalloo F, Wilson M, Hurley E, Lim Y, Maxwell AJ, Harkness EF, Howell A.
    • Breast Cancer Res Treat. 2021 Jul 26. doi: 10.1007/s10549-021-06333-1. Epub ahead of print.
    • Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
    • Kotoula V, Papadopoulou K, Tikas I, Fostira F, Vrettou E, Chrisafi S, Fountzilas E, Koliou GA, Apostolou P, Papazisis K, Zaramboukas T, Asimaki-Vlachopoulou A, Miliaras S, Ananiadis A, Poulios C, Natsiopoulos I, Tsiftsoglou A, Demiri E, Fountzilas G.
    • Breast Cancer. 2021 Jul 24. doi: 10.1007/s12282-021-01276-3. Epub ahead of print.
    • Management of patients with BRCA mutation from the point of view of a breast surgeon.
    • Riis ML.
    • Ann Med Surg (Lond). 2021 Apr 16;65:102311. doi: 10.1016/j.amsu.2021.102311.
    • Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
    • Ložar T, Žgajnar J, Perhavec A, Blatnik A, Novakovic S, Krajc M.
    • Eur J Surg Oncol. 2021 Mar 26:S0748-7983(21)00393-0. doi: 10.1016/j.ejso.2021.03.248. Epub ahead of print.
    • Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
    • Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, Walsh C, Li AJ, Rimel BJ, Karlan BY, Amersi F.
    • Am Surg. 2020 Oct;86(10):1243-1247. doi: 10.1177/0003134820964208. Epub 2020 Oct 26.
    • Re: Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.
    • Goncalves R.
    • Breast Cancer Res Treat. 2020 Aug;182(3):763-764. doi: 10.1007/s10549-020-05742-y. Epub 2020 Jun 13.
    • Letter, Commentary

    Related:

    Original research:

    Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.

    • Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer.
    • Valero MG, Moo TA, Muhsen S, Zabor EC, Stempel M, Pusic A, Gemignani ML, Morrow M, Sacchini V.
    • Br J Surg. 2020 May 20. doi: 10.1002/bjs.11616. Epub ahead of print.
    • Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.
    • Frasson AL, Lichtenfels M, de Souza AAB, Vollbrecht B, Falcone AB, Frasson MARM, Barbosa F.
    • Breast Cancer Res Treat. 2020 May;181(1):69-75. doi: 10.1007/s10549-020-05582-w. Epub 2020 Mar 25.

    Related:

    Letter, Commentary:

    Re: Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.

    • Bilateral Paget's Disease of the Breast in a Patient with CHEK2 Mutation.
    • Owusu-Brackett N, Menon PD, Nazarullah A, Jatoi I, Elmi M.
    • Eur J Breast Health. 2020 Apr 1;16(2):152-154. doi: 10.5152/ejbh.2020.5568. eCollection 2020 Apr.
    • Occult disease in reduction mammoplasties and prophylactic mastectomies.
    • Nomikos A, Husain EA, Graham AD.
    • Breast J. 2020 Apr;26(4):691-696. doi: 10.1111/tbj.13512. Epub 2019 Aug 25.
    • Risk-reducing mastectomy in germline CDH1 mutation carriers: Pathologic findings.
    • Gianella CA, Bendito B, Iglesias C, Bengoechea MP, Miñón C, Ruiz A.
    • Breast J. 2020 Mar;26(3):583-584. doi: 10.1111/tbj.13604. Epub 2019 Sep 20.
    • The Importance of Risk-Reducing Prophylactic Mastectomy in Breast Cancer (BRCA) Carriers: A Case Report.
    • Ochaney P, Patel K, Haq F, Reese R, Igel S.
    • Cureus. 2019 Aug 2;11(8):e5311. doi: 10.7759/cureus.5311.
    • A young woman's story of genetic testing and risk-reducing mastectomy.
    • [No author given]
    • FORCE. XRAYS. 2019 Jun 6.

    Related:

    Narrative: I Had a Preventive Mastectomy—Then Found Out I Already Had Breast Cancer. (Health)

    • Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report.
    • Mirandola S, Pellini F, Granuzzo E, Lorenzi M, Accordini B, Ulgelmo M, Invento A, Lombardi D, Caldana M, Pollini GP.
    • Int J Surg Case Rep. 2019 Apr 5;58:92-95. doi: 10.1016/j.ijscr.2019.03.053. [Epub ahead of print]
    • High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan.
    • Yamauchi H, Okawa M, Yokoyama S, Nakagawa C, Yoshida R, Suzuki K, Nakamura S, Arai M.
    • Breast Cancer Res Treat. 2018 Dec;172(3):679-687. doi: 10.1007/s10549-018-4953-1. Epub 2018 Sep 10.
    • Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.
    • Arai M, Yokoyama S, Watanabe C, Yoshida R, Kita M, Okawa M, Sakurai A, Sekine M, Yotsumoto J, Nomura H, Akama Y, Inuzuka M, Nomizu T, Enomoto T, Nakamura S.
    • J Hum Genet. 2018 Apr;63(4):447-457. doi: 10.1038/s10038-017-0355-1. Epub 2017 Nov 8.
    • The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study.
    • Câmara S, Pereira D, André S, Mira B, Vaz F, Oom R, Marques JC, Leal de Faria J, Rodrigues Dos Santos C.
    • Int J Breast Cancer. 2018 Jan 1;2018:1426369. doi: 10.1155/2018/1426369. eCollection 2018.
    • VUS Reclassified to "Suspected Deleterious": When Genetic Counseling Updates Become Life-Saving.
    • [No author given]
    • My Gene Counsel. 2017 Nov 30.
    • Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
    • van Zelst JCM, Mus RDM, Woldringh G, Rutten MJCM, Bult P, Vreemann S, de Jong M, Karssemeijer N, Hoogerbrugge N, Mann RM.
    • Radiology. 2017 Nov;285(2):376-388. doi: 10.1148/radiol.2017161218. Epub 2017 Jun 13.
    • Is Sentinel Lymph Node Biopsy Necessary in Patients Undergoing Prophylactic Mastectomy? A Systematic Review and Meta-Analysis.
    • Nagaraja V, Edirimanne S, Eslick GD.
    • Breast J. 2016 Mar-Apr;22(2):158-65. doi: 10.1111/tbj.12549. Epub 2016 Jan 8.
    • Meta-Analysis
    • Occult Histopathology and Its Predictors in Contralateral and Bilateral Prophylactic Mastectomies.
    • Mattos D, Gfrerer L, Ling IT, Reish RG, Hughes KS, Halpern EF, Cetrulo C, Colwell AS, Winograd JM, Yaremchuk MJ, Austen WG Jr, Liao EC.
    • Ann Surg Oncol. 2016 Mar;23(3):767-75. doi: 10.1245/s10434-015-4896-2. Epub 2015 Nov 17.
    • Conservative mastectomies for breast cancer and risk-reducing surgery: the Memorial Sloan Kettering Cancer Center experience.
    • Manning AT, Sacchini VS.
    • Gland Surg. 2016 Feb;5(1):55-62. doi: 10.3978/j.issn.2227-684X.2015.10.02.
    • Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance.
    • Manning AT, Wood C, Eaton A, Stempel M, Capko D, Pusic A, Morrow M, Sacchini V.
    • Br J Surg. 2015 Oct;102(11):1354-9. doi: 10.1002/bjs.9884. Epub 2015 Aug 27.
    • Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature.
    • Yao K, Liederbach E, Tang R, Lei L, Czechura T, Sisco M, Howard M, Hulick PJ, Weissman S, Winchester DJ, Coopey SB, Smith BL.
    • Ann Surg Oncol. 2015 Feb;22(2):370-6. doi: 10.1245/s10434-014-3883-3. Epub 2014 Jul 15.
    • Review

    Related:

    Comment / Editorial

    Safely expanding the use of nipple-sparing mastectomy in BRCA mutation carriers.

    • Total skin-sparing mastectomy in BRCA mutation carriers.
    • Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ.
    • Ann Surg Oncol. 2014 Jan;21(1):37-41. doi: 10.1245/s10434-013-3230-0. Epub 2013 Aug 28.
    • Sentinel lymph node biopsy for risk-reducing mastectomy.
    • Burger A, Thurtle D, Owen S, Mannu G, Pilgrim S, Vinayagam R, Pain S.
    • Breast J. 2013 Sep;19(5):529-32. doi: 10.1111/tbj.12157. Epub 2013 Jul 19.
    • Prophylactic mastectomy in patients at high risk: is there a role for sentinel lymph node biopsy?
    • Murthy V, Chamberlain RS.
    • Clin Breast Cancer. 2013 Jun;13(3):180-7. doi: 10.1016/j.clbc.2012.12.001. Epub 2013 Jan 26.